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Primary human cells can be transformed into tumor
cells by a defined set of genetic alterations including
telomerase, oncogenic RasV12, and the tumor sup-
pressors p53 and pRb. SV40 small T (ST) is required
for anchorage-independent growth in vitro and in
vivo. Here, we identify the Hippo tumor suppressor
pathway as a critical target of ST in cellular transfor-
mation. We report that ST uncouples YAP from the
inhibitory activity of the Hippo pathway through
PAK1-mediated inactivation of NF2. Membrane-teth-
ered activated PAK is sufficient to bypass the require-
ment for ST in anchorage-independent growth. PAK
acts via YAP to mediate the transforming effects of
ST. Activation of endogenous YAP is required for ST-
mediated transformation and is sufficient to bypass
ST in anchorage-independent growth and xenograft
tumor formation. Our findings uncover the Hippo tu-
mor suppressor pathway as a final gatekeeper to
transformation and tumorigenesis of primary cells.INTRODUCTION
Tumors are thought to arise from four to six rate-limiting, inde-
pendent stochastic oncogenic events. The in vitro creation of
tumor cells from primary cells by a defined set of genetic ele-
ments was an important experimental validation of this concept,
identifying aminimal set of pathways that together result in onco-
genic transformation (Hahn et al., 1999, 2002). This model offers
the possibility to studymolecular pathways required for transfor-
mation in a minimally disturbed genetic background: all ge-
netic alterations are known. This contrasts with patient-derived
cancer cell lines, which carry a diverse array of genetic events
that arose during selection for tumorigenesis in vivo and subse-quently for growth in cell culture. The complexity of the genetic
background complicates the analysis of mechanisms underlying
cellular transformation and properties relevant to tumorigenesis,
including anchorage-independent growth.
Viral oncogenes have been important tools in the identification
of tumor suppressor pathways in human primary cells. The p53
and p16/pRb tumor suppressor pathways were identified as
targets of SV40 large T. Hahn’s original genetically defined trans-
formation model (Hahn et al., 1999) expressed telomerase, H-
RasV12, and a construct encoding SV40 large T to target the
p14ARF/p53 and p16INK4A/pRb pathways. It was subsequently
found that SV40 small T (ST) (also encoded in the large T
construct) was required independently of large T to support
anchorage-independent growth (Hahn et al., 2002). The ability
of ST to confer anchorage-independent growth correlates with
its ability to inactivate PP2A activity. Inhibition of PP2A can
bypass the requirement for ST in cellular transformation models,
andmutations inactivating PP2A subunits have been identified in
tumors (reviewed in Sablina and Hahn, 2008; Sablina et al.,
2010). PP2A has many substrates. Among these, AKT, b-cate-
nin, and c-Myc are known to be activated by ST. However, the
combined overexpression of active forms of these proteins
only partially replaced ST in cellular transformation (Sablina
et al., 2010), suggesting that unidentified PP2A effector path-
ways might be involved.
The Hippo tumor suppressor pathway is regulated by cell po-
larity, cell contact, and mechanical forces (Wada et al., 2011;
Halder et al., 2012; Aragona et al., 2013). Hippo/MST kinase
acts via a membrane-associated complex containing the tumor
suppressor NF2/Merlin (Yin et al., 2013). MST kinases activate
LATS kinases, which in turn phosphorylate the transcriptional co-
activators YAP and TAZ, leading to their inactivation through
cytoplasmic sequestration and increased degradation (Dong
et al., 2007; Zhao et al., 2007, 2010b; Hao et al., 2008; Lei
et al., 2008). Inhibition of YAP and TAZ limits proliferation and in-
duces apoptosis (Barry and Camargo, 2013). Importantly, over-
expression of YAP is sufficient to lead to tumorigenesis in mouseCell Reports 8, 707–713, August 7, 2014 ª2014 The Authors 707
Figure 1. YAP Replaces Small T to Drive Soft Agar Growth
(A) BJT/p53kd/p16kd/RasV12 cells were transduced to express ST; a mutant form of ST unable to bind PP2A (STmutC97S/E102Q); wild-type Flag-YAP, Flag-YAPS127A, or
Flag-YAPS397A; or with empty vector as a control. S397 in human YAP corresponds to S381 in mouse. After antibiotic selection, cells were plated in soft agar or
harvested for immunoblotting. Left: images of colonies formed after 2 weeks. Right: average colony number ± SD from three independent experiments. ANOVA:
p < 0.0001 comparing ST, YAPS127A, and YAPS397A with control; p = 0.001 YAPWT versus control; mutant form of ST versus control was not significant.
Immunoblots show ST and YAP expression. Anti-ERK was used to control for loading.
(B) YAP can replace ST in HMECs. Unmodified HMECs can exhibit epigenetic changes that silence p16 (Dumont et al., 2009; Locke and Clark, 2012). Here,
HMECs were transduced to express shRNAs targeting p53 and p16 as well as vectors to express hTert, RasV12 and ST; wild-type Flag-YAP, Flag-YAPS127A, or
Flag-YAPS397A; or with empty vector as a control. ANOVA: p < 0.0001 comparing all samples versus control. Immunoblots show ST and YAP expression.
Anti-actin was used to control for loading. Error bars represent mean ± SD for three independent experiments.
(C) BJT/p53kd/p16kd/RasV12 cells were transduced with LATS2 shRNA vectors (one to three rounds). Gray: LATS2 mRNA levels relative to cells with control vector.
Black: soft agar colony formation (normalized to ST transduced cells). Colony number increase was significant for all samples by ANOVA (p = 0.002 for sh1;
p < 0.0001 for all others). Error bars represent mean ± SD for three independent experiments.
(D) Effect of LATS2 shRNA depletion on YAP S127 phosphorylation.
(E) Quantitative real-time RT-PCR tomeasure YAP target levels in control and LATS2 shRNA-treated cells. LATS2 levels shown at right. Data representmean ±SD
for three independent experiments. ANOVA: upregulation of Cyr61, Survivin and ANKRD1, p < 0.0001; CTGF, p = 0.01 for sh2, p < 0.0001 for sh1. Changes in the
PAK and TBP controls were not significant.
(F and G) Tumors from BJT/p53kd/p16kd/RasV12 cells injected subcutaneously into NOD-SCID Il2rg/mice. F: cells transduced with ST, YAPS127A, or empty vector
control (EV). (G) Cells transduced with ST, LATS2 shRNA#1, or vector control. Tumors were scored at 10 weeks.
(H) BJT/p53kd/p16kd/RasV12+ST cells were transduced to express hemagglutinin-tagged-LATS2, Tead2 dominant-negative (DN), or shRNAs to deplete YAP1 or with
relevant empty vector controls. Upper panel: soft agar colony number. p = 2 3 105 control 1 versus HA-LATS2 (t test). p < 0.0001 comparing TEAD-DN and
shYAP with control 2 (ANOVA).models (Dong et al., 2007) and can stimulate anchorage-inde-
pendent growth of partially transformed cell lines in vitro (Over-
holtzer et al., 2006; Zhang et al., 2009). Primary human fibroblasts
and epithelial cells fail to divide more than once in anchorage-in-
dependent conditions in soft agar unless they also express SV40
ST (Hahn et al., 2002; Voorhoeve and Agami, 2003). We hypoth-
esized that ST expression is required for continued proliferation
in soft agar because it alleviates Hippo pathway activity.
Here, we report that SV40 ST and the related oncogenic Mer-
kel cell polyomavirus ST activate endogenous YAP. We present
evidence that ST acts though PAK1 to inactivate the NF2 tumor
suppressor to alleviate inactivation of YAP. Activation of PAK1
at the cell membrane is sufficient to bypass the requirement
for ST. Limiting PAK1 activity blunts the transforming potential
of the ST oncoprotein. Thus, ST uncouples YAP from regulation
by the Hippo tumor suppressor pathway. Activation of YAP is708 Cell Reports 8, 707–713, August 7, 2014 ª2014 The Authorsnecessary and sufficient to replace ST in cellular transformation.
Thus, the YAP proto-oncogene is a key mediator of the trans-
forming effects of the ST oncoprotein.
RESULTS AND DISCUSSION
YAP Can Replace Small T
To test the hypothesis that the Hippo pathway acts as an effector
of SV40 ST in cellular transformation, we asked if YAP activity
could replace ST expression to support growth in soft agar.
We first confirmed that primary human fibroblasts (BJ) and hu-
man mammary epithelial cells (HMECs) expressing RasV12,
hTert, and short hairpin RNAs (shRNAs) to p53 and p16 failed
to grow in soft agar unless they also expressed ST (Figures 1A
and 1B). Transducing the cells to overexpress YAP stimulated
colony growth for both cell types in the absence of ST (Figures
Figure 2. ST Expression Increases YAP Activity
(A) YAP S127 phosphorylation in HMECT/p53kd/p16kd/RasV12 and
BJT/p53kd/p16kd/RasV12 cells transduced to express ST.
(B) Quantitative PCR of YAP targets in BJT/p53kd/p16kd/RasV12 cells ± ST. Target
increases were significant in ST-expressing cells (ANOVA p < 0.0001).
Changes in the TBP and PAK controls were not significant. Error bars repre-
sent mean ± SD for three independent experiments.
(C) Immunoblots comparing the effect of ST and YAPS127A expression onMyc,
b-catenin and Akt. The two sets of samples were run on the same gel, with an
intervening marker lane removed.1A and 1B). Mutant forms of YAP that are resistant to LATS
kinases (Zhao et al., 2010a) were more potent in supporting
colony formation. ST increased the expression of YAP targets,
including Cyr61, CTGF, Survivin/Birc5, and ANKRD1 (Fig-
ure S1A). These results indicate that the requirement for ST to
support anchorage-independent growth can be overcome by
providing YAP in these two primary human cell types.
YAP is overexpressed in some human tumors (e.g., Zhang
et al., 2009), so we considered the possibility that YAP might
bypass ST in the preceding experiments only because it was
overexpressed. To test this, we asked whether increasing the
activity of endogenous YAP could also support anchorage-inde-
pendent growth. Cells were transduced to express shRNAs to
deplete LATS2 (the major LATS kinase in these cells). LATS2
depletion was monitored by quantitative PCR (Figure 1C). As
expected, LATS2 depletion reduced YAP S127 phosphorylation,
indicating elevated YAP activity (Figure 1D). Expression of
the YAP targets Cyr61, CTGF, Survivin/Birc5, and ANKRD1
increased, reflecting elevated YAP activity (Figure 1E). Reducing
LATS2 levels gave BJ cells only a small growth advantage on
plastic (Figure S1B) but conferred a robust capacity for growth
in soft agar (Figure 1C). The effect of LATS2 depletion was
dose dependent (Figure 1C), suggesting that YAP activity is
limiting for soft agar growth in these cells. Activation of endoge-
nous YAP accounted for85% of the activity of ST in colony for-
mation in these experiments. LATS2 depletion also supported
growth of HMECs in soft agar (Figure S1C). BJ cells expressing
YAPS127A or with activation of endogenous YAP by LATS2 deple-
tion produced tumors in xenograft assays (Figures 1F and 1G).These findings provide evidence that activation of endogenous
YAP can bypass the requirement for SV40 ST in a genetically
defined model of cellular transformation.
To ask whether YAP activity is required for ST-mediated trans-
formation, we used three methods to lower YAP activity in
fully transformation-competent cells. First, LATS2 was overex-
pressed to reduce YAP activity. Second, a dominant-negative
form of TEAD (Liu-Chittenden et al., 2012) was used to lower
YAP activity. Third, two different shRNAs were used to deplete
YAP (Figure S1D). Each of these treatments reduced YAP lucif-
erase reporter activity (Figure S1E) and significantly reduced col-
ony formation in soft agar (Figure 1H). Comparable results were
obtained following YAP depletion in HMECs (Figure S1F). Thus,
YAP activity is required for anchorage-independent growth in
these primary cells. YAP activity is both necessary and sufficient
for full transformation of cells expressing oncogenic forms of Ras
and ST.
ST Acts on YAP
Since activation of endogenous YAP was sufficient to replace
ST, we askedwhether YAP is amolecular target of ST. Activation
of the Hippo pathway leads to phosphorylation of LATS1/2 by
MST1/2. LATS1/2 in turn phosphorylate YAP on multiple sites,
including S127, which promotes cytoplasmic retention of YAP
(Zhao et al., 2007; Hao et al., 2008; Lei et al., 2008), and S381
(S397 in human YAP1), which promotes YAP turnover (Zhao
et al., 2010b). Expression of ST decreased YAPS127 phosphory-
lation in BJ fibroblasts and in HMECs (Figure 2A). Consistent with
the decrease in YAPS127 phosphorylation, ST increased expres-
sion of the YAP target genes (Figure 2B). Thus, ST upregulates
YAP activity.
The ST oncoprotein has been reported to act via the cellular
proto-oncogenes AKT, b-catenin, and c-Myc (Sablina et al.,
2010). Given that YAP can replace ST, we considered the possi-
bility that YAPmight indirectly activate the other ST effectors.We
confirmed that ST expression increased c-Myc levels and
increased phosphorylation of AKT on S437 and Thr308 in BJ
cells (Figure 2C; b-catenin was not affected). BJ cells expressing
YAPS127A in place of ST showed no increase in Myc expression
or AKT phosphorylation (Figure 2C). Yet, these cells were fully
capable of anchorage-independent growth (Figure 1A). Thus,
Myc and AKT do not need to be hyperactivated in the presence
of active YAP. ST expression normally activates all these path-
ways concurrently, and it is likely that their combined activity
contributes to cellular transformation. Our findings provide evi-
dence that activating endogenous YAP can account for much
of the transforming activity of ST, independent of previously
described ST effector pathways.
Merkel Cell Carcinoma
To explore the relevance of the relationship between ST and YAP
in human cancer, we turned toMerkel cell carcinoma, an aggres-
sive skin cancer that depends onMerkel cell polyomavirus (MCV)
ST activity (Feng et al., 2008; Shuda et al., 2011). Like SV40
ST, MCV ST is required for anchorage-independent growth of
MCV-transformed cells (Shuda et al., 2011). MCV ST reduced
phosphorylation of YAP on Ser127 (Figure 3A) and was able to
support anchorage-independent growth (Figure 3B). MCV STCell Reports 8, 707–713, August 7, 2014 ª2014 The Authors 709
Figure 3. Merkel Cell Carcinoma ST Increases YAP Activity
BJT/p53kd/p16kd/RasV12 cells were transduced to express MCV ST or with empty vector control.
(A) Immunoblots showing the effect of MCV ST on YAP S127 phosphorylation.
(B) Soft agar colony formation: mean ± SD for three independent experiments. p < 0.001 comparing MCV-ST with control (t test).
(C) Cells were transfected with 8xGTIIC-luciferase reporter and transduced to express SV40 ST or MCV ST. Data represent the average of three independent
experiments ± SD. ANOVA: p < 0.001 for SV40ST; p < 0.0001 for MCV-ST.
(D) Effects of reducing YAP activity on colony formation by MCV-ST. ANOVA: p < 0.0001 experiments versus their respective controls. Error bars represent
mean ± SD for three independent experiments. LATS denotes LATS2. C denotes control.also increased YAP activity in a luciferase reporter assay (Fig-
ure 3C). To assess the contribution of YAP to MCV-ST activity,
we used three methods to lower YAP activity in fully transforma-
tion-competent cells expressing MCV-ST: expression of domi-
nant-negative TEAD, expression of LATS2, and expression of
shRNAs to deplete YAP (shRNA efficiency is shown in Figure S2).
Each of these treatments significantly reduced colony formation
in soft agar (Figure 3D). Thus, activation of endogenous YAP is
required for the transforming activity of oncogenic MCV ST.
ST Acts via PAK1 on YAP Activity
ST inhibits PP2A activity (Cho et al., 2007). A mutant form of ST
that is unable to bind to PP2A was severely compromised in its
ability to induce colony formation (Figure 1A). PP2A has been re-
ported to complex with Mob1/Mats to regulate phosphorylation
of the Hippo pathway core kinases (Ribeiro et al., 2010; Couzens
et al., 2013). Inhibition of PP2A in this context should increase
MST and LATS phosphorylation, leading to increased LATS-
mediated phosphorylation of YAP. Instead, we observed a
decrease in YAP phosphorylation upon ST expression (Figures
2A and 3A). Thus, the activation of YAP by ST is unlikely to be
mediated directly via PP2A on Hippo pathway core components.
This prompted us to explore other potential Hippo regulators
with known PP2A associations. PAK1 kinase has been linked
to PP2A (Westphal et al., 1999; Taglieri et al., 2011). PAK1 can
phosphorylate and inactivate the tumor suppressor neurofibro-
min 2 (NF2; Shaw et al., 2001; Xiao et al., 2002). Depletion of
NF2 leads to activation of YAP (Zhang et al., 2010) by preventing
recruitment of LATS kinases to cytoplasmic membranes, where
they are activated byMST kinases (Yin et al., 2013).We reasoned
that ST might act on the Hippo pathway via activation of PAK1.
ST expression led to an increase in PAK1 protein and active
phospho-PAK1T423 (Figure 4A) while having little or no effect
on PAK1 mRNA (Figure 2B). Interestingly, this led to an increase
in the amount of PAK1 associated with cellular membranes (Fig-
ure 4B), raising the possibility that membrane association of
PAK1 might mediate the effect of ST on the Hippo pathway.
Expression of membrane-tethered PAK1CAAX (Manser et al.,
1997) carrying the activating mutation T423E proved to be suffi-
cient to replace ST, whereas wild-type PAK1CAAX was not (Fig-710 Cell Reports 8, 707–713, August 7, 2014 ª2014 The Authorsures 4C and S3B). Expression of ST or PAK1CAAX-T423E led to
reduced YAPS127A phosphorylation, consistent with an increase
in YAP activity; other forms of PAK were less effective (Fig-
ure S3A). Like ST, expression of membrane-tethered PAK1T423E
increased the phosphorylation of NF2 (Figure 4D). Thus, acti-
vated PAK1 was able to replace ST in blocking NF2 activity
and was sufficient to support anchorage-independent growth
when localized to the membrane.
To ask whether PAK1 is required for ST-mediated transforma-
tion, we made a membrane-tethered kinase-inactive form of
PAK1 (K299A), which acts as a dominant negative (He et al.,
2008). Expression of PAK1CAAX-K299A did not compromise prolif-
eration under normal culture conditions (cytoplasmic PAKK299A
impaired proliferation). PAK1CAAX-K299A strongly reduced soft
agar growth of cells expressing Rasv12 and ST (Figure 4E). Inter-
estingly,membrane-tethered PAK1K299Awasmuch less effective
in reducing colony formation when expressed in cells where ST
had been replaced by YAPS127A (Figure 4E). PAK1 can also acti-
vate ERK, independent of PAK kinase activity (Wang et al., 2013).
We examined ERK phosphorylation in cells expressing mem-
brane-tethered forms of PAK, activated PAK and kinase-inactive
PAK. The level of ERK phosphorylation was similar, suggesting
that ERK activation was independent of PAK kinase activity in
these cells. However, the ability of these PAK-CAAX proteins to
support soft agar growth correlated with their effect on YAPS127
phosphorylation (Figure S3A). Thus, the effects of membrane
associated PAK on anchorage-independent growth appear to
be independent of the ERK pathway. In the absence of other
methods to selectively manipulate PAK activity at the cell mem-
brane, we cannot exclude the possibility that membrane-teth-
ered kinase-inactive PAK might have additional effects.
As an independent means to lower PAK activity in colony-for-
mation assays, we used the inhibitor IPA-3 (Deacon et al., 2008).
Interestingly, IPA-3 treatment compromised colony formation by
ST-expressing cells at concentrations that did not impair colony
formation by YAPS127A-expressing cells (Figure 4F). Thus, inhib-
iting PAK blunts the transforming potential of ST.
Next, we asked whether YAP acts downstream of membrane-
tethered activated PAK. Expression of shRNAs to deplete
YAP reduced colony formation by cells expressing ST or
Figure 4. PAK1 Is Required to Mediate the Transforming Effect of ST
(A) Immunoblots showing the effect of ST on PAK1 and PAK1 phosphorylation in BJT/p53kd/p16kd/RasV12 cells ±ST.
(B) Immunoblots showing the subcellular localization of PAK1 and control proteins. Cells were fractionated into membrane (MB) cytoplasmic (Cyt) and nuclear
(Nuc) fractions. N-Cadherin, membrane marker; cMyc, nuclear marker. Note the relative increase of PAK1 in the membrane fraction of the ST-expressing cells.
(C) Soft agar colony formation by BJT/p53kd/p16kd/RasV12 cells transduced to express ST or variants of PAK1. Data represent the mean ± SD for three independent
experiments. ANOVA: ***p < 0.0001 versus control. ns: not significant.
(D) BJT/p53kd/p16kd/RasV12 cells were transduced to express ST or activated PAK1L107F-CAAX. Immunoblots show the expression of NF2. Actin was used as a loading
control. The phosphorylated form of NF2 is inactive and migrates slower in SDS-PAGE.
(E) Soft agar colony formation by BJT/p53kd/p16kd/RasV12 cells transduced to express ST or YAPS127A ± PAK1K229A-CAAX. Data represent the mean ± SD for three
independent experiments. **p < 0.01 (t test).
(F) Soft agar colony formation by BJT/p53kd/p16kd/RasV12 cells transduced to express SV40 or MCV ST or YAPS127A. Cells were treated with the PAK inhibitor IPA-3.
Data represent the mean ± SD for three independent experiments.
(G) Soft agar colony formation by BJT/p53kd/p16kd/RasV12 cells transduced to express ST (left) or PAK1T423E-CAAX (right). Cells were transduced to express shRNAs to
deplete YAP or to overexpress LATS2. Data represent the mean ± SD for three independent experiments. ANOVA: ***p < 0.0001 versus control.membrane-tethered activated PAKT423E (Figure 4G). Similarly,
blocking Hippo pathway activity by overexpressing LATS2
reduced colony formation by ST- or PAKT423E-expressing cells
(Figure 4G).
Theexperiments in Figures4E–4Gprovideevidence that theST
oncoprotein acts via PAK1 at the cell membrane to regulate the
Hippo pathway. The importance of this mechanism is shown by
the finding that inhibition of PAK1 can compromise ST-mediated
transformation while having relatively little effect on YAP-medi-
ated transformation. We have provided evidence that PAK con-
tributes to oncogenic transformation through activation of the
YAP proto-oncogene and that activation of YAP is a key require-
ment for ST in transformation of primary humancells. YAP activity
is required downstream of ST and activated PAK1, serving as a
gatekeeper for anchorage-independent growth.
EXPERIMENTAL PROCEDURES
Antibodies, plasmids, primers, and standard methods are described in
Supplemental Experimental Procedures.
Viral Transduction
Ecotropic and amphotropic retroviruses were made as described previously
(Brummelkamp et al., 2002). Supernatant from transfected Ecopack2 andPhoenix-Ampho cells was harvested at 36–48 hr and frozen in aliquots. Cells
were plated to reach 70% confluence when infected with virus overnight in
the presence of 8 mg/ml polybrene. Antibiotic selection was started at 36 hr.
HMECs and BJ cells were first retrovirally transduced to express the ecotropic
receptor for subsequent transductions by ecotropic retroviruses (Voorhoeve
and Agami, 2003).
Soft Agar Assay
A total of 43 104 cells were resuspended in 2 ml 0.375% low-gelling-temper-
ature agarose (Sigma-Aldrich, A-9045) in Dulbecco’s modified Eagle’s me-
dium (DMEM), 10% serum, seeded in triplicate in six-well plates coated with
1% low-gelling agarose in DMEM, 10% serum. A total of 1 ml of DMEM,
10% fetal calf serum (BJ cells), or MGEM bullet kit medium (HMECs) was
added weekly. Colonies were stained with 0.75 mg/ml 3-(4,5-dimethythia-
zol)-2,5-diphenyl tetrazolium bromide after 2–3 weeks and imaged. Colony
counting was automated (MATLAB). Data were analyzed using ANOVA or a
two-tailed t test (unequal variance), as indicated.
Luciferase Assays
8xGTIIC (Dupont et al., 2011) was used to monitor YAP/TEAD activity in
HEK293 cells. Firefly luciferase activity was normalized to a Renilla luciferase
transfection control and to empty vector controls. Dual luciferase assays were
performed (Bio-Rad).
Tumorigenic Growth in NOD-SCID Mice
Animal work was carried out according to institutional guidelines (Institute
of Molecular and Cell Biology [IMCB] Institutional Animal Care and UseCell Reports 8, 707–713, August 7, 2014 ª2014 The Authors 711
Committee number 120768). Approximately 23 106 cells were injected subcu-
taneously in each flank of immunocompromised NOD-SCID Il2rg/ mice
(Chen et al., 2009). Tumor growth was monitored every 3–4 days. Mice were
sacrificed when tumors reached 2 cm in diameter.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
three figures, and one table and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2014.06.062.
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